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In the developed world, the tuberculosis
sanitariums were shuttered when antibi-
otics became widely available. But tuber-
culosis (TB), a disease of poverty, still fes-
ters across wide swaths of the developing
world. The World Health Organization’s
2008 report estimated that in 2006, 1.5 mil-
lion people died of TB, as well as 0.2 million
people also infected with HIV. TB is slow
growing and can remain latent in the lungs
for years, complicating diagnosis. The
WHO estimates that 2 billion people in
the world have latentTB, whereas 14.4mil-
lion people live with active TB (http://www.
who.int/tb/publications/global_report/2008/
key_points/en/index.html).
Public health experts worry about two
trends: the blistering rate of HIV infection,
which makes people more susceptible to
TB, and the growing realization that our
‘‘antibiotics honeymoon’’ may be over.
Half a million cases of multidrug resistant
TB were reported in 2006. ‘‘Obviously,
this is extremely worrying for everybody,
because if they get a hold they are difficult
to treat and the cure rate is very low,’’ said
Dr. Tanya Parish, professor of mycobac-
teriology at Queen Mary’s School of Med-
icine and Dentistry (UK) and senior scien-
tist/principal investigator at the Seattle,
WA, based Infectious Disease Research
Institute (IDRI [http://www.idri.org]). ‘‘In
parts of Eastern Europe and Russia, these
resistant strains are becoming a big prob-
lem, so it is not necessarily going to be
confined to. developing countries.’’ Her
group collaborates with the TB Global Alli-
ance, validating proteases as drug targets.
New Trends, Old Foe
‘‘TB is really an underdog,’’ said Peg Will-
ingham, senior director for external affairs
at Rockville, MD, based Aeras Global TB
Vaccine Foundation (http://www.aeras.
org), which develops TB vaccines. ‘‘It kills
so many people each year and is the lead-
ing cause of death for people with HIV/
AIDS in Africa. Because it has been around
for literally thousands of years, it is part of
the background or wallpaper in public
health.’’ According to Willingham, TB is
only now getting increased attention.
Organizations like the Gates Founda-
tion and the National Institutes of Health
(NIH) are now pouring money into public
health measures for TB but are emphasiz-
ing ‘‘translational research.’’ By investing
in not-for-profit biotechs and product de-
velopment partnerships (PDPs) that use
private sector strategies, they hope that
know-how borrowed from industry can
be turned to the public good.
Normally, TB is curable by a cheap,
daily 2–4 drug regimen that takes 6–9
months. But when people don’t adhere
to treatment, multiple-drug-resistant
(MDR) or extensively drug-resistant
(XDR) strains of TB can result. Treating
drug-resistant TB can take years, and
the available drugs do not work for every-
body.
The only TB vaccine available, Bacillus
Calmette-Guerin (BCG), developed in
1921 and still used in the developing world
and parts of Europe, fails to protect most
people beyond childhood, as it doesn’t
stop pulmonary transmission. Addition-
ally, most diagnosis in developing coun-
tries is done by a sputum smear test devel-
oped by Robert Koch in 1882. The smear
test is not as sensitive as a culture—it
only picks up TB about half the time—but
it is much faster, as a negative culture
can take from 3 to 4 weeks to determine.
Bootstrapping a Cure
Steve Reed, PhD, founded IDRI, ‘‘to bring
biotech and research together focusing
on diseases of poverty.’’ Reed has ap-
pointments as professor of medicine at
Cornell University Medical College in
New York and research professor of
pathobiology at the University of Wash-
ington, but his calling is as a serial entre-
preneur, establishing parallel for-profit
and nonprofit biotechs. In 1993, Reed
started IDRI, where he is chief scientific
officer. The next year, Reed cofounded
Corixa, a for-profit biotech. ‘‘That com-
pany ended up developing adjuvants
that were of benefit to IDRI,’’ Reed said.
‘‘There was scientific and business syn-
ergy between the two organizations. Basi-
cally, the institute provided a challenge
and a way to do good for the company,
and the company provided developmen-
tal, manufacturing, and clinical expertise
that a small research organization doesn’t
fill.’’
When Corixa was bought by GlaxoS-
mithKline in 2005 for $300 million, Reed
refocused his energies on IDRI. The orga-
nization started pulling in substantial NIH
funding and Gates Foundation grants:
$47 million to develop a leishmaniasis
vaccine through clinical trials and, in
2007, $29 million to develop adjuvants
for a malaria vaccine (in collaboration
with the PATH Malaria Vaccine Initiative
[http://www.malariavaccine.org] and the
World Health Organization). This year,
IDRI received a $6.3 million grant from
the National Institute of Allergy and Infec-
tious Diseases (NIAID) to develop adju-
vants for TB vaccines. Corporate collabo-
rators include 3M, which donated IP from
its toll-like receptor TLR7 and TLR8 ago-
nists for vaccine adjuvants.
‘‘We started our antigen program with
Glaxo and Corixa in 1995 and identified
more than 100 mycobacteria antigens,’’
said Rhea Coler, Ph.D., vice president of
preclinical biology. ‘‘The vaccine candi-
date resulting from this collaboration is
now in phase II trials. Building on this ex-
perience, IDRI is working on its own TB
vaccine, intended for drug-resistant TB
as well. IDRI has also developed in-house
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that is in phase I evaluation. On the diag-
nostics front, IDRI is collaborating on
new tests for leishmaniasis, leprosy, and
tuberculosis. We also have a program
for chlamydia as well as programs devel-
oping vaccine adjuvants and TB antibi-
otics.’’
Paying for It All
Aside from grants, IDRI sustains itself by
leveraging internally generated IP. ‘‘To
sustain an organization that we believe is
fundamentally important, you have to
use innovative public-private partnership
practices,’’ Reed said. ‘‘We think that
our work is of high enough quality that it
should be commercializable.’’
According to Reed, the main impact
would be in the developing countries,
but the world is changing quickly. Brazil,
India, Russia, and China are at an interest-
ing crossroad as being real markets as
well as real customers. ‘‘But we always re-
tain the rights for what we call public sec-
tor marketing, so the technology we de-
velop doesn’t get priced out of reach of
those who need it the most,’’ Reed said.
Recently, Reed cofounded another
company, Immune Design, to develop se-
lective vaccines and synthetic adjuvants
targeted at dendritic cells. ‘‘Immune De-
sign is probably the first biotech to be
started with a global access strategy in-
herent in its mission,’’ said Reed.
IDRI is now being run by Steve Davis,
former CEO of Corbis, a Gates-backed
company. ‘‘We are basically trying to cre-
ate something new here,’’ said Davis.
‘‘Some of the most critical early and trans-
lational science is done by federal and
philanthropic grants. You need to use
a nonprofit model to secure these grants.
In our instance, we would not take it to
market. You need the for-profit commu-
nity for marketing.’’
While the NIH and the Gates Founda-
tion are IDRI’s largest source of funding,
according to Davis, global licensing and
commercial partnerships can give IDRI
a revenue stream and milestone pay-
ments. An emerging concept in the global
health field is that organizations have
a global access plan and can enter into
arrangements to get royalties for tax ex-
empt research so it is accessible at cost
to developing countries.
Aeras: One-Stop Shopping for TB
Vaccines
The Aeras Global TB Vaccine Foundation
was founded in 2003 as a spinoff of
Maryland BIOTECH Sequella. The 130
person nonprofit biotech intends to de-
velop a TB vaccine by 2016. ‘‘The word ev-
erybody uses in the nonprofit TB drug field
is accessibility,’’ said Peg Willingham.
‘‘People have got to afford them, or have
somebody pay for them, so that they can
afford the therapies.’’
In 2007, The Gates Foundation
awarded Aeras $200 million over 5 years
to push a TB vaccine through phase II,
building on a 2003 grant. Aeras estimates
it will cost $120 million to bring a TB vac-
cine candidate to phase III trials. Aeras
has six vaccine candidates in the pipeline,
two in preclinical, two in phase I/II, and
one in phase II.
‘‘Our ideal would be a vaccine that
would prevent initial infection and later re-
infection,’’ said Willingham. ‘‘At a mini-
mum . it should be 60% effective. No
vaccines on the market are 100% effec-
tive.’’ Production has to scale very
cheaply to 100 million doses a year. To
that end, Aeras has its own in-house vac-
cine manufacturing facility.
‘‘Our strategy is called a prime boost
strategy,’’ said Dr. Lewellys Barker, senior
medical advisor. Aeras is developing an
improved BCG vaccine for newborns. Ac-
cording to Barker, BCG is a live vaccine,
and Aeras’s goal is to modify it so it over-
expresses certain antigens to make it
safer, particularly for patients with HIV.
Long-term follow-up studies suggest
that TB vaccine protection doesn’t last,
so a booster is necessary.
Aeras, along with Nevada-based Cru-
cell, has developed AERAS-402/Crucell
Ad35, a replication-deficient adenovirus
that expresses TB antigens meant to elicit
high levels of CD8+ T cell responses.
AREAS-402/Crucell AD35 completed a
phase I clinical trial in the US in 2006.
Another phase I trial started in South
Africa in 2007 in healthy adults vaccinated
at birth with BCG.
Aeras is currently partnering with the
South African Tuberculosis Vaccine Initia-
tive of the University of Capetown (http://
www.satvi.edu) to test the Oxford Univer-
sity MVA viral-vector vaccine. According
to Willingham, South Africa has good
technical capabilities and infrastructure.
It also has a high rate of endemic TB,
which is necessary for testing the vaccine
in large and varied populations to get sig-
nificant data. Aeras also has agreements
in Kenya, India, Uganda, and Cambodia.
‘‘First we have to get a vaccine that
works well,’’ said Barker. ‘‘And that is
the challenge in TB. We don’t know what
kind of immune response we need to get
for a recipient to be protected.’’ Accord-
ing to Barker, cell-mediated responses
are thought to be important, but the role
of antibodies is unknown. A major accom-
plishment will be the ability to gauge T cell
responses. ‘‘Aside from a better regime
for immunizing against TB, we would like
it to work for people infected with HIV,’’
Barker said.
Aeras also has a few preclinical pro-
jects: an oral vaccine using a bacterio-
phage capsid inserted in attenuated shi-
gella bacteria as well as an inhaled
vaccine being tested on animals at Tulane
University in New Orleans. Barker noted
that it is uncertain whether animal tests
could predict vaccine performance in
people or what would be the indication
of the immune response needed for ani-
mals. Researchers do not know what
immune response is needed to judge the
effectiveness of early childhood immuni-
zation. ‘‘Clinical testing will be difficult,
as diagnosis of TB in early childhood is
difficult,’’ said Barker.
‘‘We have relatively little drug-resistant
TB in this country, but this not really true
in the rest of the world,’’ said Barker.
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